151 related articles for article (PubMed ID: 9477124)
41. Children's cancer group trials of interleukin-2 therapy to prevent relapse of acute myelogenous leukemia.
Sievers EL; Lange BJ; Sondel PM; Krailo MD; Gan J; Tjoa T; Liu-Mares W; Feig SA
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S39-44. PubMed ID: 10685657
[TBL] [Abstract][Full Text] [Related]
42. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
[TBL] [Abstract][Full Text] [Related]
43. Histamine: a novel approach to cancer immunotherapy.
Hellstrand K; Brune M; Naredi P; Mellqvist UH; Hansson M; Gehlsen KR; Hermodsson S
Cancer Invest; 2000; 18(4):347-55. PubMed ID: 10808371
[TBL] [Abstract][Full Text] [Related]
44. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
45. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
[TBL] [Abstract][Full Text] [Related]
46. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.
Karp JE; Smith BD; Levis MJ; Gore SD; Greer J; Hattenburg C; Briel J; Jones RJ; Wright JJ; Colevas AD
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4467-73. PubMed ID: 17671131
[TBL] [Abstract][Full Text] [Related]
47. Impact of IL-1β and the IL-1R antagonist on relapse risk and survival in AML patients undergoing immunotherapy for remission maintenance.
Grauers Wiktorin H; Aydin E; Christenson K; Issdisai N; Thorén FB; Hellstrand K; Martner A
Oncoimmunology; 2021; 10(1):1944538. PubMed ID: 34367728
[TBL] [Abstract][Full Text] [Related]
48. Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia.
Bassan R; Raimondi R; Lerede T; D'emilio A; Buelli M; Borleri G; Personeni A; Bellavita P; Rodeghiero F; Barbui T
Haematologica; 1998 Jul; 83(7):627-35. PubMed ID: 9718868
[TBL] [Abstract][Full Text] [Related]
49. Histamine dihydrochloride: inhibiting oxidants and synergising IL-2-mediated immune activation in the tumour microenvironment.
Agarwala SS; Sabbagh MH
Expert Opin Biol Ther; 2001 Sep; 1(5):869-79. PubMed ID: 11728221
[TBL] [Abstract][Full Text] [Related]
50. Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia.
Benyunes MC; Massumoto C; York A; Higuchi CM; Buckner CD; Thompson JA; Petersen FB; Fefer A
Bone Marrow Transplant; 1993 Aug; 12(2):159-63. PubMed ID: 8401364
[TBL] [Abstract][Full Text] [Related]
51. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML).
Jehn U; Heinemann V; Wilmanns W
Anticancer Res; 1989; 9(1):119-24. PubMed ID: 2705739
[TBL] [Abstract][Full Text] [Related]
52. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
53. Immunotherapy with interleukin 2 after ABMT in AML.
Hamon MD; Prentice HG; Gottlieb DJ; Macdonald ID; Cunningham JM; Smith OP; Gilmore M; Gandhi L; Collis C
Bone Marrow Transplant; 1993 May; 11(5):399-401. PubMed ID: 8504274
[TBL] [Abstract][Full Text] [Related]
54. Two-Stage Priming of Allogeneic Natural Killer Cells for the Treatment of Patients with Acute Myeloid Leukemia: A Phase I Trial.
Kottaridis PD; North J; Tsirogianni M; Marden C; Samuel ER; Jide-Banwo S; Grace S; Lowdell MW
PLoS One; 2015; 10(6):e0123416. PubMed ID: 26062124
[TBL] [Abstract][Full Text] [Related]
55. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
[TBL] [Abstract][Full Text] [Related]
56. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
[TBL] [Abstract][Full Text] [Related]
57. Interleukin 2 treatment in acute myelogenous leukemia.
Mandelli F; Vignetti M; Tosti S; Andrizzi C; Foa R; Meloni G
Stem Cells; 1993 Jul; 11(4):263-8. PubMed ID: 8401249
[TBL] [Abstract][Full Text] [Related]
58. Histamine H
Monczor F; Copsel S; Fernandez N; Davio C; Shayo C
Handb Exp Pharmacol; 2017; 241():141-160. PubMed ID: 27316911
[TBL] [Abstract][Full Text] [Related]
59. [Immunotherapy with interleukin-2 and allogenic LAK cells in a patient with acute myeloblastic leukemia].
Parrado A; Casares S; Carmona M; Campo T; Rodríguez Fernández JM
Sangre (Barc); 1994 Oct; 39(5):393-6. PubMed ID: 7754446
[TBL] [Abstract][Full Text] [Related]
60. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
Teichmann JV; Ludwig WD; Thiel E
Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]